Refractive Error - Myopia Severe, Refractive Error - Myopia Simple
Conditions
Brief summary
The purpose of this study is to evaluate the initial safety of the UV-FS laser in humans.
Interventions
DEVICEWaveLight® Ultraviolet Femtosecond (FS) Laser System
Utilizes ultraviolet (UV) light with a wavelength of 347 nanometers (nm) for refractive error correction
PROCEDURELaser Assisted Lenticular Extraction
Used for refractive error correction
Sponsors
Alcon Research
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Photopic distance visual acuity worse than best corrected visual acuity (BCVA) 20/400 in the study eye; * Myopia with manifest refraction spherical equivalent (MRSE) of - 1.50 diopter (D) or higher in the study eye; * Able to comprehend and provide documented informed consent; * Willing and able to comply with schedule for follow-up visits; * Minimum required endothelial cell density (ECD) in study eye as outlined in the protocol; * Presence of natural lens in study eye; * A treatment simulation with spectacles or contact lenses on the study eye does not negatively impact participant's daily activities; * Other protocol-specified inclusion criteria may apply.
Exclusion criteria
* Pregnant or nursing; * Acute or chronic disease or illness that would increase the operative risk or confound the outcomes of the study as clinically assessed by the Investigator; * Active implanted device, including but not limited to, heart pacemaker or defibrillator, for which laser use may be a contraindication; * Current use of medications with known ocular side effects; * Predicted residual stromal bed thickness \<300 micrometers (μm) in study eye * Ocular conditions in the study eye; * Previous ocular surgery in the study eye that resulted in corneal distortions within the treatment zone; * Residual, recurrent or active ocular disease that may impact study outcomes; * Previous or current diagnosis of dry eye; * Known allergic reaction to medications expected to be used preoperatively, during laser refractive surgery, and for postoperative care; * Pre-existing corneal opacities in study eye; * Contact lens worn in study eye and not removed prior to study testing affected by wear per timeframe specified in the protocol; * Other protocol-specified
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean percentage change in average endothelial cell density (ECD) from screening to each visit post procedure | Screening, Up to Month 6 (post-operative) | Specular microscopy will be performed on the study eye and endothelial cell density will be recorded. |
| Presence of optical treatment zone corneal haze | Up to Month 6 (post-operative) | Corneal haze will be assessed on a scale of 0 to 4, where 0 = clear or no haze can be seen, and 4 = opacity is visible without slit lamp, greatly obscures iris detail. |
| Mean change from screening in presence of disruption in the integrity of retinal layers in the macula | Screening, Up to Month 6 (post-operative) | Retinal layer integrity will be assessed by a posterior segment ocular coherence tomography (OCT) scan of the study eye. Any disruption (change) in the retinal layers in the macula as compared to the screening scan will assess retinal integrity. |
| Mean percentage change in lens opacification from screening to each visit post procedure | Screening, Up to Month 6 (post-operative) | A Scheimpflug scan will be performed to evaluate any opacification of the crystalline lens in the study eye and a Pentacam Nucleus Staging (PNS) grade from 0 to 5 will be assigned. |
| Mean percentage change in foveal thickness from screening to each visit post procedure | Screening, Up to Month 6 (post-operative) | Foveal thickness will be assessed by a posterior segment OCT scan of the study eye. |
Countries
Ireland, Singapore, United States
Outcome results
None listed